Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGF βi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Conditions:   Anatomic Stage IV Breast Cancer AJCC v8;   HER2-Negative Breast Carcinoma Interventions:   Procedure: Biospecimen Collection;   Procedure: Computed Tomography;   Drug: Gemcitabine;   Procedure: Magnetic Resonance Imaging;   Biological: Naxitamab;   Biological: Universal Donor Expanded TGF-beta-imprinted NK Cells Sponsor:   Margaret Gatti-Mays Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials